Lumos Pharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for rare diseases. Its product includes LUM-201, an oral growth hormone stimulating small molecule for the treatment of pediatric growth hormone deficiency (PGHD). The company was founded on June 4, 1999 and is headquartered in Austin, TX.
Company profile
Website
CEO
Richard J. Hawkins
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
383830503
Latest ownership filings
Institutional ownership, Q3 2020
43.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 38 |
Opened positions | 3 |
Closed positions | 10 |
Increased positions | 9 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 50.07 mm |
Total shares | 3.62 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Deerfield Management | 936.29 k | $12.94 mm |
NEA Management | 526.66 k | $7.28 mm |
BX Blackstone | 468.15 k | $6.47 mm |
Lion Point Capital | 407.19 k | $5.63 mm |
Renaissance Technologies | 306.11 k | $4.23 mm |
Opaleye Management | 240.89 k | $3.33 mm |
Vanguard | 221.55 k | $3.06 mm |
Jefferies | 120.65 k | $1.67 mm |
WFC Wells Fargo & Co. | 116.39 k | $1.61 mm |
BLK Blackrock | 68.66 k | $950.00 k |